It is very uncertain whether gemcitabine changes overall response rate compared with vandetanib (very low certainty).
It is very uncertain whether gemcitabine plus S‐1 changes overall response rate compared with S‐1 (very low certainty).
It is very uncertain whether gemcitabine plus cisplatin changes overall response rate compared with S‐1 plus cisplatin (very low certainty).
It is very uncertain whether gemcitabine plus vandetanib changes overall response rate compared with vandetanib (very low certainty).
It is very uncertain whether gemcitabine plus oxaliplatin changes overall response rate compared with best supportive care (very low certainty).
It is very uncertain whether gemcitabine plus oxaliplatin changes overall response rate compared with 5‐fluorouracil plus folinic acid (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine plus mitomycin C changes overall response rate compared with capecitabine plus mitomycin C (very low certainty).